Powered by: Motilal Oswal

News

Biocon chief Kiran Mazumdar-Shaw appointed member of Court of Regents at Royal College of Surgeons, Edinburgh Biocon Ltd and Biocon Biologics Ltd Executive Chairperson Kiran Mazumdar-Shaw has been appointed as Regent of the Royal College of Surgeons of Edinburgh (RCSed), a Biocon release said on Thursday. On her appointment as the latest member to the College’s Court of Regents, Mazumdar-Shaw said: "I am humbled and deeply honoured to be appointed Regent of the Royal College of Surgeons Edinburgh. As the oldest surgical college in the world with just under 30,000 members in 100 countrie...
Biocon chief Kiran Mazumdar-Shaw appointed member of Court of Regents at Royal College of Surgeons, Edinburgh
Biocon chief Kiran Mazumdar-Shaw appointed member of Court of Regents at Royal College of Surgeons, Edinburgh
Source: IANS
7/09/2023 8:25:07 PM
Neutral Biocon Ltd For Target Rs. 240 - Motilal Oswal Financial Services Ltd Steady progress in generics/research services * Biocon (BIOS) delivered lower-than-estimated earnings in 1QFY24, mainly led by inferior performance in the biologics segment (57% of 1QFY24 sales). This was offset to some extent by a healthy show in generics and research services. BIOS continues to make efforts to enhance offerings and resolve regulatory issues in the biologics segment. * We cut our earnings estimates by 14%/5% for FY24/FY25, factoring in a) higher rebates for certain pro...
Neutral Biocon Ltd For Target Rs. 240 - Motilal Oswal Financial Services Ltd
Neutral Biocon Ltd For Target Rs. 240 - Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services
16/08/2023 12:49:56 PM
Biocon registers Rs 3,516 crore revenues in Q1, up 59% YoY Indian pharmaceuticals giant Biocon registered Rs 3,516 crore revenues for Quarter 1 of FY 2024. An official statement issued by the company on Thursday said that the profits were up by 59 per cent year-on-year. The revenues of biosimilars are up by 106 per cent while that of research services are up by 25 per cent, the statement said.    "We have had a strong start to the year. At a consolidated level, revenues rose 59 per cent YoY to Rs 3,516 crore driven primarily by t...
Biocon registers Rs 3,516 crore revenues in Q1, up 59% YoY
Biocon registers Rs 3,516 crore revenues in Q1, up 59% YoY
Source: IANS
11/08/2023 10:10:47 AM
Biocon Biologics announces key leadership appointments, Rhonda Duffy to be COO Biocon Biologics, a subsidiary of pharmaceutical giant Biocon Ltd, has made several key leadership appointments which will play an important role in transforming the organisation and realising its ambition of building a global biosimilars leader. As per a company statement, Rhonda Duffy has been appointed Chief Operating Officer (COO) and will lead manufacturing, quality, and supply chain management. She brings over 30 years of experience in the global pharmaceuticals industry. Dr. Sand...
Biocon Biologics announces key leadership appointments, Rhonda Duffy to be COO
Biocon Biologics announces key leadership appointments, Rhonda Duffy to be COO
Source: IANS
5/08/2023 9:29:41 AM
Tech Stars : Biocon Ltd and Samvarshana Motherson International Ltd By Religare Broking Biocon Ltd. Buy Biocon Ltd. CMP:253.20, Initiation Range252-254, Stop Loss 242, Target 279 TECHNICAL RATIONALE – We are seeing noticeable traction across the pharma pack, after the breakout in the pharma index. Biocon has also resumed the trend post breakout from a reversal pattern with noticeable surge in the volumes. It has also reclaimed the long term moving average i.e. 200 EMA and forming a fresh buying pivot now. Traders should use this phas...
Tech Stars : Biocon Ltd and Samvarshana Motherson International Ltd By Religare Broking
Tech Stars : Biocon Ltd and Samvarshana Motherson International Ltd By Religare Broking
Source: Religare Broking Ltd
12/07/2023 12:34:23 PM
Biocon rises after its arm launches HULIO injection in United States Biocon is currently trading at Rs. 264.20, up by 0.80 points or 0.30% from its previous closing of Rs. 263.40 on the BSE. The scrip opened at Rs. 266.60 and has touched a high and low of Rs. 270.40 and Rs. 263.65 respectively. So far 110754 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 341.50 on 19-Jul-2022 and a 52 week low of Rs. 191.60 on 21-Mar-2023. Last one week high and low of the scrip stood at Rs. 270...
Biocon rises after its arm launches HULIO injection in United States
Biocon rises after its arm launches HULIO injection in United States
Source: Accord Fintech
4/07/2023 11:02:14 AM
Hold Biocon Ltd For Target Rs.235 - ICICI Direct Viatris integration propels numbers; focus on Hulio launch, pending queries..   About the stock: Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene). Biocon Biologics (BBL), a subsidiary of Biocon, entered into an arrangement to acquire Viatris’ biosimilars assets for US$3.34 billion. • Biosimilar US pipeline: (approvals - bPegfilgrastim, bTrastuzumab, bGlargine, bAdalimumab) • In ...
Hold Biocon Ltd For Target Rs.235 - ICICI Direct
Hold Biocon Ltd For Target Rs.235 - ICICI Direct
Source: ICICI Direct
13/06/2023 3:41:59 PM
Hold Biocon Ltd For Target Rs.250 - ICICI Securities Tepid organic growth   Biocon Limited’s (Biocon) Q4FY23 performance was boosted by consolidation of the acquired business of biosimilars (segment revenue up 114% YoY) from Viatris. Reported gross margin was inflated by ~150bps and EBITDA margin by 360bps due to licensing income of Rs1.75bn. Biocon is gearing up for regulatory clearances of Malaysian and Bengaluru facilities which will likely pave the way for approval of Aspart and Adalimumab. While growth in biologics has so ...
Hold Biocon Ltd For Target Rs.250 - ICICI Securities
Hold Biocon Ltd For Target Rs.250 - ICICI Securities
Source: ICICI Securities Ltd
7/06/2023 3:23:14 PM
Neutral Biocon Ltd For Target Rs. 260 - Motilal Oswal Financial Services Ltd * BIOS delivered lower-than-expected 4QFY23 operational performance, led by lower traction in biologics (ex-licensing income) and generics business. This was offset to some extent by strong execution in Research services (Syngene) business. * We reduce our earnings estimate by 6%/2% for FY24/FY25 to factor a) in reduction in vaccine business, on account of restructuring of a deal with Serum institute, b) regulatory delays for key approvals (b-aspart/bbevacizumab), and c) sustained momentum...
Neutral Biocon Ltd For Target Rs. 260 - Motilal Oswal Financial Services Ltd
Neutral Biocon Ltd For Target Rs. 260 - Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
26/05/2023 2:59:04 PM
Biocon gains on reporting 46% rise in Q4 consolidated net profit Biocon is currently trading at Rs. 243.90, up by 1.65 points or 0.68% from its previous closing of Rs. 242.25 on the BSE. The scrip opened at Rs. 257.35 and has touched a high and low of Rs. 259.50 and Rs. 243.40 respectively. So far 1845255 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 344.00 on 10-Jun-2022 and a 52 week low of Rs. 191.60 on 21-Mar-2023. Last one week high and low of the scrip stood at Rs. 25...
Biocon gains on reporting 46% rise in Q4 consolidated net profit
Biocon gains on reporting 46% rise in Q4 consolidated net profit
Source: Accord Fintech
24/05/2023 3:15:33 PM
India's Serum to double investment in Biocon's unit to $300 million The Serum Institute of Life Sciences will double its investment in one of Biocon Ltd's units, giving it access to 100 million doses of vaccines annually along with the distribution rights to Serum's vaccine portfolio, the Indian biopharma firm said on Tuesday. Serum Institute of Life Sciences is a unit of Serum Institute of India, the world's biggest vaccine maker. Under new terms of the alliance, it would pump in $150 million after converting a loan to Biocon Pharma Ltd int...
India's Serum to double investment in Biocon's unit to $300 million
India's Serum to double investment in Biocon's unit to $300 million
Source: Reuters
25/04/2023 9:54:18 AM
Buy Biocon Ltd For Target Rs. 365 - JM Financial Institutional Securities Focus on Viatris integration BIOS’ 3Q results included Viatris consolidation driving 35%/32% YoY growth in Revenue/EBITDA respectively albeit one-off deal expenses led to reported loss, adjusting for which the PAT was at Rs1.4bn (19% beat). Biosimilars revenue grew 54%YoY to INR 15.1bn in 3Q and is expected to further improve to INR 20bn+ in 4Q. Serum deal is expected to close in 1H24 pending Mumbai NCLT approval. Semglee, Fulphila gained further market share while Hulio continues to...
Buy Biocon Ltd For Target Rs. 365 - JM Financial Institutional Securities
Buy Biocon Ltd For Target Rs. 365 - JM Financial Institutional Securities
Source: JM Financial Institutional Securities Ltd
21/02/2023 12:45:49 PM
Biocon Q3FY23 revenue at Rs 3,020 crore, up 36% Global biopharmaceuticals company Biocon Ltd on Tuesday announced its net revenue from operations for the quarter, ending December 31, 2022. increased by 36 per cent to Rs 3,020 crore from Rs 2,223 crore in the same period last year. Executive Chairperson, Biocon and Biocon Biologics Kiran Mazumdar-Shaw said: "Q3 FY23 has been an eventful quarter which saw the completion of the global acquisition of our partnered Biosimilars business from Viatris on Nov 29, 2022. "We are now i...
Biocon Q3FY23 revenue at Rs 3,020 crore, up 36%
Biocon Q3FY23 revenue at Rs 3,020 crore, up 36%
Source: IANS
15/02/2023 10:54:09 AM
Buy Biocon Ltd For Target Rs. 395 - JM Financial Institutional Securities Viatris deal closure: Emergence of an Integrated biosimilar play The completion of USD 3.34bn Viatris acquisition paves the way for an integrated global biosimilar play. We closely watch the execution and forward integration synergies in developed markets for existing products, elimination of transfer pricing and revenue visibility from new launches (bHulio and bKixelle) which will drive operating leverage. This will be partly offset by higher opex, amortisation and finance costs. BIOS has...
Buy Biocon Ltd For Target Rs. 395 - JM Financial Institutional Securities
Buy Biocon Ltd For Target Rs. 395 - JM Financial Institutional Securities
Source: JM Financial Institutional Securities Ltd
29/12/2022 12:35:39 PM
Biocon rises on the BSE Biocon is currently trading at Rs. 273.70, up by 4.10 points or 1.52% from its previous closing of Rs. 269.60 on the BSE. The scrip opened at Rs. 272.95 and has touched a high and low of Rs. 276.85 and Rs. 270.20 respectively. So far 88814 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 410.50 on 08-Feb-2022 and a 52 week low of Rs. 258.30 on 17-Oct-2022. Last one week high and low of the scrip stood at Rs. 276....
Biocon rises on the BSE
Biocon rises on the BSE
Source: Accord Fintech
23/12/2022 10:44:53 AM
Biocon inches up on starting clinical study of Itolizumab for Ulcerative Colitis in India Biocon is currently trading at Rs. 271.70, up by 0.05 points or 0.02% from its previous closing of Rs. 271.65 on the BSE. The scrip opened at Rs. 272.05 and has touched a high and low of Rs. 273.65 and Rs. 269.50 respectively. So far 58465 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 410.50 on 08-Feb-2022 and a 52 week low of Rs. 258.30 on 17-Oct-2022. Last one week high and low of the scrip stood at Rs. 277....
Biocon inches up on starting clinical study of Itolizumab for Ulcerative Colitis in India
Biocon inches up on starting clinical study of Itolizumab for Ulcerative Colitis in India
Source: Accord Fintech
15/12/2022 12:31:57 PM
Neutral Biocon Ltd For Target Rs.300 - Motilal Oswal Financial Services On the verge of Viatris deal closure Work in progress to strengthen biosimilar pipeline * Biocon (BIOS) delivered an operationally in-line quarter. While biologics/ generics sales continued to ramp-up on higher volume off-take, the profitability was hurt to some extent by intensified competition. Syngene’s superior execution led to the improvement in overall operating profit for 2Q. * We maintain our EPS estimates for FY23/FY24. We value BIOS on an SoTP basis (at an EV/EBITDA o...
Neutral Biocon Ltd For Target Rs.300 - Motilal Oswal Financial Services
Neutral Biocon Ltd For Target Rs.300 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
12/12/2022 10:43:19 AM
Buy Biocon Ltd For Target Rs.395 - JM Financial Institutional Securities Viatris deal closure: Emergence of an Integrated biosimilar play The completion of USD 3.34bn Viatris acquisition paves the way for an integrated global biosimilar play. We closely watch the execution and forward integration synergies in developed markets for existing products, elimination of transfer pricing and revenue visibility from new launches (bHulio and bKixelle) which will drive operating leverage. This will be partly offset by higher opex, amortisation and finance costs. BIOS has...
Buy Biocon Ltd For Target Rs.395 - JM Financial Institutional Securities
Buy Biocon Ltd For Target Rs.395 - JM Financial Institutional Securities
Source: JM Financial Institutional Securities Ltd
12/12/2022 9:31:52 AM
Vikram Kirloskar, Toyota Kirloskar vice-chairman, passes away Vikram Shreekant Kirloskar, an eminent industrialist and Vice-Chairman of Toyota Kirloskar Motors passed away after suffering a cardiac arrest late Tuesday. He was 64. His funeral is scheduled for 1 p.m. on Wednesday in Bengaluru, according to family sources. Toyota India tweeted, "We are extremely saddened. At this time of grief, we request everyone to pray that his soul rests in peace." Karnataka Chief Minister Basavaraj Bommai condoled the death. "Heartfelt condolen...
Vikram Kirloskar, Toyota Kirloskar vice-chairman, passes away
Vikram Kirloskar, Toyota Kirloskar vice-chairman, passes away
Source: IANS
30/11/2022 12:50:34 PM
Biocon Biologics completes acquisition of Viatris Inc Biocon Biologics Ltd, a subsidiary of listed biopharmaceutical company Biocon Ltd, on Tuesday announced the completion of its acquisition of global biosimilars business of its partner Nasdaq listed Viatris Inc. Biocon Biologics and Viatris have obtained all applicable approvals from key global regulators, including the US Federal Trade Commission, the Competition Commission of India, the Reserve Bank of India, and its investors, a company statement said. The acquisition provides Biocon ...
Biocon Biologics completes acquisition of Viatris Inc
Biocon Biologics completes acquisition of Viatris Inc
Source: IANS
30/11/2022 9:51:10 AM
Biocon inches up on signing semi-exclusive partnership agreement with Zentiva Biocon is currently trading at Rs. 280.75, up by 0.65 points or 0.23% from its previous closing of Rs. 280.10 on the BSE. The scrip opened at Rs. 283.10 and has touched a high and low of Rs. 283.10 and Rs. 280.55 respectively. So far 5005 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 410.50 on 08-Feb-2022 and a 52 week low of Rs. 258.30 on 17-Oct-2022. Last one week high and low of the scrip stood at Rs. 293.3...
Biocon inches up on signing semi-exclusive partnership agreement with Zentiva
Biocon inches up on signing semi-exclusive partnership agreement with Zentiva
Source: Accord Fintech
24/11/2022 10:41:24 AM
Neutral Biocon Ltd For Target Rs.320 - Motilal Oswal Financial Services Multiple headwinds affect earnings Viatris acquisition, Vaccine deal, and potential approvals to drive performance from 2HFY23 * BIOS delivered a lower than expected 1QFY23, led by reduced traction in the Generics segment, stable performance in Biosimilars, and higher operational cost. It continues to build its Biosimilars pipeline on its own and via the partnership model, as well as launch molecules in the Generics space. * We cut our FY23/FY24 EPS estimate by 20%/6%, factoring in: ...
Neutral Biocon Ltd For Target Rs.320 - Motilal Oswal Financial Services
Neutral Biocon Ltd For Target Rs.320 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
8/09/2022 3:12:50 PM
Biocon gains on divesting 5.4% stake in Syngene International Biocon is currently trading at Rs. 295.20, up by 2.95 points or 1.01% from its previous closing of Rs. 292.25 on the BSE. The scrip opened at Rs. 292.40 and has touched a high and low of Rs. 296.50 and Rs. 292.00 respectively. So far 31802 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 410.50 on 08-Feb-2022 and a 52 week low of Rs. 290.25 on 06-Sep-2022. Last one week high and low of the scrip stood at Rs. 304....
Biocon gains on divesting 5.4% stake in Syngene International
Biocon gains on divesting 5.4% stake in Syngene International
Source: Accord Fintech
7/09/2022 12:05:17 PM
Buy Biocon Ltd For Target Rs.400 - Centrum Broking EBITDA miss; Biosimilar outlook stands positive Biocon has reported 1QFY23 result healthy sales growth of 21.5% YoY to Rs21.4bn. While the EBITDA margin at 18.7% (~344bps YoY and 589bps QoQ) continued to be under pressure due to higher overheads costs (Staff/ R&D/ other costs were up 18%/65%/61% YoY), expenses were higher due to annual increments and increased input & freight cost. Adjusted for Rs 380 mn of forex loss (includes MTM translation loss of Rs 430 mn related to Goldman&r...
Buy Biocon Ltd For Target Rs.400 - Centrum Broking
Buy Biocon Ltd For Target Rs.400 - Centrum Broking
Source: Centrum Broking Ltd
30/07/2022 11:10:25 AM
Biocon Q1FY23 revenue up 23% at Rs 2,217 cr Global biopharmaceuticals company Biocon on Wednesday reported 23 per cent rise in revenue for the first quarter of financial year 2023, at Rs 2,217 crore. "We have had a strong start to the year. At a consolidated level, YoY revenues grew 23 per cent backed by robust growth in both Biosimilars (29 per cent) and Generics (19 per cent). Core earnings before interest, taxes, depreciation, and amortisation (EBITDA) grew 25 per cent and margin improved to 31 per cent compared to 30 per ce...
Biocon Q1FY23 revenue up 23% at Rs 2,217 cr
Biocon Q1FY23 revenue up 23% at Rs 2,217 cr
Source: IANS
28/07/2022 9:08:25 AM
Biocon`s arm gets EU GMP certification for new biologics manufacturing facility in Bengaluru Biocon’s subsidiary -- Biocon Biologics has received EU GMP certificate from the Health Products Regulatory Authority (HPRA), Ireland, for its new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru, following a GMP inspection in April 2022. The facility, spread across 340,000-square feet, will enhance capabilities manifold to manufacture drug substance of mAbs portfolio and will enable to serve patients across the globe. This integrated,...
Biocon`s arm gets EU GMP certification for new biologics manufacturing facility in Bengaluru
Biocon`s arm gets EU GMP certification for new biologics manufacturing facility in Bengaluru
Source: Accord Fintech
6/07/2022 9:29:08 AM
Biocon moves up on planning to acquire 26% stake in AREREPL Biocon is currently trading at Rs. 312.20, up by 1.90 points or 0.61% from its previous closing of Rs. 310.30 on the BSE. The scrip opened at Rs. 309.50 and has touched a high and low of Rs. 312.75 and Rs. 309.50 respectively. So far 4227 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 414.30 on 19-Jul-2021 and a 52 week low of Rs. 308.25 on 29-Jun-2022. Last one week high and low of the scrip stood at Rs. 339.8...
Biocon moves up on planning to acquire 26% stake in AREREPL
Biocon moves up on planning to acquire 26% stake in AREREPL
Source: Accord Fintech
30/06/2022 9:38:19 AM
Biocon zooms as its arm, Viatris launch third Oncology Biosimilar ‘Abevmy’ in Canada Biocon is currently trading at Rs. 340.05, up by 17.10 points or 5.29% from its previous closing of Rs. 322.95 on the BSE. The scrip opened at Rs. 325.55 and has touched a high and low of Rs. 340.65 and Rs. 325.55 respectively. So far 100617 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 420.25 on 11-Jun-2021 and a 52 week low of Rs. 314.90 on 25-Oct-2021. Last one week high and low of the scrip stood at Rs. 34...
Biocon zooms as its arm, Viatris launch third Oncology Biosimilar ‘Abevmy’ in Canada
Biocon zooms as its arm, Viatris launch third Oncology Biosimilar ‘Abevmy’ in Canada
Source: Accord Fintech
20/05/2022 3:09:15 PM
Hold Biocon Ltd For Target Rs.356 - ICICI Securities Generics & research grow; biosimilar stagnates Biocon Limited (Biocon) has reported Q4FY22 financials above our estimates led by strong growth in generics and research services. While biosimilars grew 48% YoY due to launch of Semglee in the US, it has remained flat QoQ. Generics business and research services grew 25.7% and 15.1% YoY, respectively. Consolidated revenue grew 30.8% YoY to Rs24.1bn (I-Sec: Rs22.9bn), adjusted EBITDA margin improved 90bps YoY (210bps QoQ) to 24.6% (I-Sec: ...
Hold Biocon Ltd For Target Rs.356 - ICICI Securities
Hold Biocon Ltd For Target Rs.356 - ICICI Securities
Source: ICICI Securities Ltd
2/05/2022 2:26:57 PM
Key News - Indian Oil Corporation, Biocon Biologics Limited, Wipro, Vedanta Limited, Ltd By ARETE Securities Key News Indian Oil launches methanol-blended petrol on pilot basis in Assam Indian Oil Corp (IOC) rolled out M15 petrol -- 15 per cent blend of methanol with petrol -- on a pilot basis in Assam's Tinsukia district. Union Minister of State for Petroleum and Natural Gas Rameswar Teli launched the M15 petrol in the presence of Niti Aayog member VK Saraswat and IOC chairman SM Vaidya on Saturday. Teli said that blending fuel with methanol will provide respite from the rising pric...
Key News - Indian Oil Corporation, Biocon Biologics Limited, Wipro, Vedanta Limited, Ltd By ARETE Securities
Key News - Indian Oil Corporation, Biocon Biologics Limited, Wipro, Vedanta Limited, Ltd By ARETE Securities
Source: ARETE Securities Ltd
2/05/2022 9:48:29 AM
Biocon Q4 net profit down 43.72% at Rs 38.10 cr The company reported standalone net profit of Rs 38.10 crore for the quarter ended March 31, 2022 as compared to Rs 67.70 crore in the same period last year, registering a year-on-year decline of 43.72 per cent. Net revenue of the company rose by 5.31 per cent at Rs 517.70 crore in January-March quarter of this fiscal as against Rs 491.60 crore in the corresponding period last year. During January-March quarter, operating expenses increased by 15.66 per cent to Rs 491.20 crore from Rs 424....
Biocon Q4 net profit down 43.72% at Rs 38.10 cr
Biocon Q4 net profit down 43.72% at Rs 38.10 cr
Source: Dion Global Solutions Ltd
29/04/2022 10:10:57 AM
Hold Biocon Ltd For Target Rs. 390 - ICICI Direct Viatris deal - High risk-reward play with leverage… About the stock: Biocon is a leading biopharma company operating in biologics, contract research (Syngene), small molecules and branded formulations. * Biosimilar US pipeline: (approvals - Pegfilgrastim, Trastuzumab, Glargine, Adalimumab); filed - Aspart and Bevacizumab * Revenue breakup FY21: biosimilars (37%), generics (31%), CRAMS (29%)   Event: Biocon Biologics to acquire Viatris’ biosimilars asset * B...
Hold Biocon Ltd For Target Rs. 390 - ICICI Direct
Hold Biocon Ltd For Target Rs. 390 - ICICI Direct
Source: ICICI Direct
26/03/2022 12:26:31 PM
Hold Biocon Ltd For Target Rs.390 - ICICI Direct Viatris deal - High risk-reward play with leverage… About the stock: Biocon is a leading biopharma company operating in biologics, contract research (Syngene), small molecules and branded formulations. * Biosimilar US pipeline: (approvals - Pegfilgrastim, Trastuzumab, Glargine, Adalimumab); filed - Aspart and Bevacizumab * Revenue breakup FY21: biosimilars (37%), generics (31%), CRAMS (29%)   Event: Biocon Biologics to acquire Viatris’ biosimilars asset *&n...
Hold Biocon Ltd For Target Rs.390 - ICICI Direct
Hold Biocon Ltd For Target Rs.390 - ICICI Direct
Source: ICICI Direct
19/03/2022 11:04:35 AM
Neutral Biocon Ltd For Target Rs.385 - Motilal Oswal Biosimilar deal with Viatris completes the value chain in its Biologics business * BIOS recently announced that its subsidiary, Biocon Biologics (BBL), has entered into a definitive agreement with Viatris to acquire its Biosimilar business for USD3.3b. * The deal enhances BBL’s commercial/regulatory capabilities in developed markets and gives it the option to acquire b-Aflibercept (a potential Biosimilar asset). * The valuation, based on estimates shared by the management, sta...
Neutral Biocon Ltd For Target Rs.385 - Motilal Oswal
Neutral Biocon Ltd For Target Rs.385 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
12/03/2022 10:01:38 AM
Reduce Biocon Ltd For Target Rs.315 - Edelweiss Financial Services Viatris deal: Necessary but at a huge cost Biocon Biologics Limited, a subsidiary of Biocon, plans to acquire Viatris’s biosimilars assets for USD3.335bn. The deal – valued at ~16.7x CY22 EBITDA – includes cash of up to USD2.335bn and Compulsorily Convertible Preference Shares (CCPS) in BBL, valued at USD1bn. With this acquisition, Biocon gains the entire suite of economic interests and sales force, but without any major pipeline assets(except bEylea, where Biocon has ...
Reduce Biocon Ltd For Target Rs.315 - Edelweiss Financial Services
Reduce Biocon Ltd For Target Rs.315 - Edelweiss Financial Services
Source: Edelweiss Financial Services Ltd
2/03/2022 1:05:22 PM
Biocon trades higher as its arm gets nod for Posaconazole Delayed-Release tablets from USFDA Biocon is currently trading at Rs. 407.70, up by 7.75 points or 1.94% from its previous closing of Rs. 399.95 on the BSE. The scrip opened at Rs. 403.00 and has touched a high and low of Rs. 410.50 and Rs. 399.60 respectively. So far 214880 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 424.75 on 18-Feb-2021 and a 52 week low of Rs. 314.90 on 25-Oct-2021. Last one week high and low of the scrip stood at Rs. 410...
Biocon trades higher as its arm gets nod for Posaconazole Delayed-Release tablets from USFDA
Biocon trades higher as its arm gets nod for Posaconazole Delayed-Release tablets from USFDA
Source: Accord Fintech
8/02/2022 11:06:22 AM
Mid Cap : Buy Biocon Ltd For Target Rs.460 - Geojit Financial Strong performance across all segments Biocon Limited is an integrated biopharmaceutical company engaged in discovering, developing and producing biologics in chronic therapies. Key products include statins, immunosuppressants, anti-diabetic drugs and specialty enzymes. * Q3FY22 revenue rose 17.1% YoY to Rs. 2,174cr, driven by strong growth in Biosimilars (+27.6% YoY) and Research services (+9.7% YoY). * EBITDA grew by 25.4% YoY to Rs. 537cr, with a margin of 24.7% (vs. 23.0% Q3FY21)...
Mid Cap : Buy Biocon Ltd For Target Rs.460 - Geojit Financial
Mid Cap : Buy Biocon Ltd For Target Rs.460 - Geojit Financial
Source: Geojit Financial Services Ltd
8/02/2022 10:07:33 AM
Hold Biocon Ltd For Target Rs.374 - ICICI Securities Q3 witnesses recovery but regulatory hurdles persist Biocon Limited (Biocon) reported better-than-estimated revenue and PAT, but missed our estimate on the margin front. Biosimilar segment revenue grew 32.2% QoQ, mainly due to initial supply of interchangeable Semglee in the US. Generics business and research services grew 8.3% and 9.7% YoY, respectively. Consolidated revenue grew 17.5% YoY to Rs21.7bn (I-Sec: Rs18.8bn), adjusted EBITDA margin improved 90bps YoY (-170bps QoQ) to 22.5% (I-S...
Hold Biocon Ltd For Target Rs.374 - ICICI Securities
Hold Biocon Ltd For Target Rs.374 - ICICI Securities
Source: ICICI Securities Ltd
4/02/2022 9:23:50 AM
Hold Biocon Ltd For Target Rs.410 - ICICI Direct Biosimilar traction buoys up Q3, momentum to be key About the stock: Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene). * Robust biosimilar portfolio with partners like Viatris, Sandoz (for future launches), Adagio among others. Biosimilar US pipeline: (Approvals - Pegfilgrastim, Trastuzumab, Glargine, Adalimumab); filed - Aspart and Bevacizumab. Global footprint in +120 countries for biosimilars * In g...
Hold Biocon Ltd For Target Rs.410 - ICICI Direct
Hold Biocon Ltd For Target Rs.410 - ICICI Direct
Source: ICICI Direct
24/01/2022 10:10:05 AM
Biocon gains on reporting 18% rise in Q3 consolidated net profit Biocon is currently trading at Rs. 372.40, up by 8.50 points or 2.34% from its previous closing of Rs. 363.90 on the BSE. The scrip opened at Rs. 363.00 and has touched a high and low of Rs. 373.95 and Rs. 356.05 respectively. So far 109426 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 456.00 on 21-Jan-2021 and a 52 week low of Rs. 314.90 on 25-Oct-2021. Last one week high and low of the scrip stood at Rs. 373...
Biocon gains on reporting 18% rise in Q3 consolidated net profit
Biocon gains on reporting 18% rise in Q3 consolidated net profit
Source: Accord Fintech
21/01/2022 12:20:23 PM
Neutral Biocon Ltd For Target Rs.360 - Motilal Oswal On course to revive earnings growth We recently met with BIOS’ management to understand its business outlook in greater detail. Here are the key takeaways: * After two years (FY20/FY21) of earnings decline, BIOS is well-positioned to revive earnings growth meaningfully. * In addition to steady traction in already launched Biosimilars, BIOS has Insulin Glargine (Semglee) contracts starting 4QFY22. This would be further supported by bAspart, subject to regulatory clearance. * ...
Neutral Biocon Ltd For Target Rs.360 - Motilal Oswal
Neutral Biocon Ltd For Target Rs.360 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
7/12/2021 10:32:53 AM
Update On Biocon By Motilal Oswal Operationally in line with our estimate * Revenue grew 5.5% YoY to INR18.4b (est. INR19.2b) in 2QFY22. * Revenue growth was led by: * a) Research services (33% of sales), up 17% YoY to INR6.1b. * b) Biosimilars (40% of sales), up 9.8% YoY to INR7.4b. * c) Novel Biologics contribution of INR121m (nil in 2QFY21). * Growth was dragged lower by generic sales, which fell 11.5% YoY to INR5.3b (27% of sales). * Gross margin (GM) contracted by 40bp YoY to 65% due to a change in t...
Update On Biocon By Motilal Oswal
Update On Biocon By Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
1/11/2021 10:21:07 AM
Quote on Biocon Q2FY22 number below expectation, stock down 6% By Mr. Yash Gupta, Angel One Ltd Below is quote on Biocon Q2FY22 number below expectation, stock down 6% by Mr. Yash Gupta, Equity Research Analyst, Angel One Ltd    Biocon Limited reported revenue from operation at 1840 crores up by 5%, YoY 1750 crores in Q2FY21, Biosimilars has done well for the company up by 10% at ₹743 crores while generics down by 12% at ₹530 crores. The company reported an EBITDA of ₹551 crores up by 35% YoY on the back of better profit margins and product mix...
Quote on Biocon Q2FY22 number below expectation, stock down 6% By Mr. Yash Gupta, Angel One Ltd
Quote on Biocon Q2FY22 number below expectation, stock down 6% By Mr. Yash Gupta, Angel One Ltd
Source: Angel One Ltd
22/10/2021 3:52:00 PM
Biocon Q2FY22 revenue up by 10% at Rs 1,945 crore Biocon, the global biopharmaceuticals company of India, on Friday said its Q2FY22 revenue growth was up by 10 per cent at Rs 1,945 crore, primarily driven by good performance of the Research Services and Biosimilars business segments. Announcing consolidated financial results for the second quarter ending September 30, 2021, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics, said the factors responsible for the profit reported a growth of 17 per cent and 10 per cent r...
Biocon Q2FY22 revenue up by 10% at Rs 1,945 crore
Biocon Q2FY22 revenue up by 10% at Rs 1,945 crore
Source: IANS
22/10/2021 11:30:41 AM
Hold Biocon Ltd For Target Rs.410 - ICICI Direct Maiden foray into vaccines via Serum alliance… About the stock: Biocon is a leading biopharma company operating in biologics, contract research (Syngene), small molecules and branded formulations * Revenue breakup: Biosimilars (37%), generics (31%), CRAMS (29%) * Biosimilar/Insulin US pipeline- (Launched - Pegfilgrastim, Trastuzumab, Glargine; Aspart (expected in FY22E) and Bevacizumab (delayed)   Event: Biocon Biologics and Serum Institute Life Sciences Strategi...
Hold Biocon Ltd For Target Rs.410 - ICICI Direct
Hold Biocon Ltd For Target Rs.410 - ICICI Direct
Source: ICICI Direct
19/10/2021 10:01:53 AM
Biocon jumps on launching Everolimus tablets in US Biocon is currently trading at Rs. 369.85, up by 4.70 points or 1.29% from its previous closing of Rs. 365.15 on the BSE. The scrip opened at Rs. 368.50 and has touched a high and low of Rs. 370.40 and Rs. 366.90 respectively. So far 29483 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 487.70 on 23-Dec-2020 and a 52 week low of Rs. 327.75 on 23-Aug-2021. Last one week high and low of the scrip stood at Rs. 370....
Biocon jumps on launching Everolimus tablets in US
Biocon jumps on launching Everolimus tablets in US
Source: Accord Fintech
4/10/2021 11:49:28 AM
Neutral Biocon Ltd For Target Rs.410 - Motilal Oswal Adds Vaccines as a new growth dimension Commercial benefit to kick in from 2HFY23E onwards * Biocon Biologics (BBL) has entered a strategic alliance with Serum Institute Life Sciences (SILS) for commercialization of SILS’ vaccine portfolio. The alliance would develop antibodies targeting several other infectious diseases as well. * As per the agreement, BBL will receive 100m doses of vaccines from SILS annually. Assuming USD2-5 per dose, the revenue potential is to the tune o...
Neutral Biocon Ltd For Target Rs.410 - Motilal Oswal
Neutral Biocon Ltd For Target Rs.410 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
25/09/2021 10:38:06 AM
Key News - Lupin Ltd, FDI, KEC International Ltd, Welspun India Ltd, Biocon By ARETE Securities Key News FDI key to India's aspiration to be a $5 trn economy, says Deloitte CEO Foreign Direct Investment (FDI) is critically important for India to become a USD 5 trillion economy, Deloitte CEO Punit Renjen said while noting that over two-fifths of the 1,200 business leaders surveyed in the US, UK, Japan and Singapore are planning additional or first-time investments in India. Referring to the survey, he said India continues to be "one of the most attractive" FDI destina...
Key News - Lupin Ltd, FDI, KEC International Ltd, Welspun India Ltd, Biocon By ARETE Securities
Key News - Lupin Ltd, FDI, KEC International Ltd, Welspun India Ltd, Biocon By ARETE Securities
Source: ARETE Securities Ltd
20/09/2021 9:25:41 AM